Targets › SGCB
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Neurology; next expected readout Aug 2028.
Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. (UniProt, Q16585)
Open in Phaseline: the race on SGCB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sarepta Therapeutics | SRP-9003 Gene transfer therapy encoding beta-sarcoglycan (β-SG); scAAVrh74.MHCK7.hSGCB | SGCB | Phase 3 | Limb-girdle Muscular Dystrophy; Limb Girdle Muscular Dystrophy | Aug 2028 |
Limb-girdle Muscular Dystrophy (1) Limb Girdle Muscular Dystrophy (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.